A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

NCT05280275 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma
Neoplasms
Neoplasms, Plasma Cell
Gammopathy, Monoclonal
Paraproteinemias
Blood Protein Disorders
Haematologic Disease
Corneal Disease

Interventions

DRUG: Belantamab Mafodotin-Blmf
DRUG: Daratumumab
DRUG: Lenalidomide
DRUG: Dexamethasone

Sponsor

Hellenic Society of Hematology

Collaborators

[object Object]